TIL Analysis Service: Quantifying CAR-T Density & Phenotype Post-Vesicle Treatment

Online Inquiry

Background Service What We Can Offer Workflow Highlights FAQs Contact

Accurately quantifying CAR-T cells after vesicle treatment is challenging due to the complex interplay of receptor dynamics, phenotypic heterogeneity, and the suppressive tumor microenvironment. Our platefprm is designed to validate TME-remodeling strategies and optimize CAR-T persistence through high-precision measurement. Our service leverages advanced multi-omics profiling and high-dimensional flow cytometry to deliver a comprehensive assessment of CAR-T density, functional status, and phenotypic shifts. By providing deep, data-driven insights into how vesicle-based treatments alter CAR-T behavior, we empower you to overcome solid tumor barriers and accelerate the development of more effective immunotherapies.

Introduction

Following vesicle treatment, the density and phenotypic profile of CAR-T cells undergo significant remodeling, directly impacting their cytotoxic potential and persistence within the tumor microenvironment. Our TIL analysis provides precise, multiparametric quantification of these post-treatment changes, enabling researchers to dissect vesicle-induced modulation and optimize CAR-T therapeutic performance.

Fig.1 Determining CAR-T density and phenotypic changes within TILs after vesicle-based treatment. (Creative Biolabs Original) Fig.1 Quantitative evaluation of CAR-T abundance and phenotype within tumor-infiltrating lymphocytes after vesicle treatment.

Our Service

In solid tumor therapy, accurately assessing the spatial organization and functional state of tumor-infiltrating lymphocytes is critical for determining therapeutic outcomes. Creative Biolabs offers a specialized analytical platform to measure how CAR-T cells respond within the tumor microenvironment, especially after exposure to engineered vesicles such as OMVs or exosomes. Our approach helps evaluate whether therapeutic cells retain progenitor-like properties, maintain optimal receptor density for antigen engagement, and effectively resist suppressive signals originating from the tumor.

What We Can Offer

Our portfolio delivers integrated solutions to precisely quantify CAR-T cell density, phenotypic evolution, and functional dynamics following vesicle-based treatments using advanced cytometry and label-free technologies.

Featured services of quantifying CAR-T density & phenotype post-vesicle treatment at Creative Biolabs. (Creative Biolabs Original)

Our Service Process

Required Starting Materials:

Cryopreserved TIL / CAR-T Samples.
Tumor Biopsy / Ex vivo Fragments.
Vesicle Characterization Data: Basic profiles of the engineered vesicles used in the treatment.

Key Steps:

Workflow of quantifying CAR-T density & phenotype post-vesicle treatment at Creative Biolabs. (Creative Biolabs Original)

Final Deliverables:

Comprehensive Analytical Report.
Raw Multi-Omics Data.
Strategic Optimization Summary.

Key Advantages

Dual-Target Quantification: Our method distinguishes and quantifies both CAR-T cells and their derived extracellular vesicles, moving beyond traditional analysis.
High-Resolution Phenotyping: It enables precise assessment of CAR-T differentiation, exhaustion status (PD-1, TIGIT), and CAR expression intensity using multiparameter flow cytometry.
Comprehensive Vesicle Characterization: Our approach integrates nanoparticle tracking analysis for EV concentration and flow cytometry for surface CAR density, allowing direct comparison between vesicles and parent cells.

FAQ

Q1: How does vesicle treatment actually affect CAR-T density?

A1: Tumor-derived vesicles commonly promote receptor ubiquitination followed by internalization. Our platform precisely measures this loss of surface CAR expression, enabling you to design receptors with enhanced stability and sustained function.

Q2: Is this service compatible with allogeneic (off-the-shelf) platforms?

A2: Yes. We regularly analyze iPSC‑derived T and NK cells, focusing on key persistence indicators and assessing GvHD‑related risk factors, making our service fully adaptable to various allogeneic cell therapy platforms.

Why Choose Us?

Choose us for precise, multiparametric TIL analysis that quantifies CAR-T density, tracks phenotypic shifts post-vesicle treatment, and reveals rare subset dynamics. Our pipeline ensures high-resolution immune profiling, enabling you to interpret therapy response, optimize dosing, and advance cell-based immunotherapy with confidence.

Customer Reviews

"Creative Biolabs' TIL profiling provided an exceptionally detailed understanding of how tumor-derived exosomes drive terminal exhaustion in CAR-NKT cells. Their focus on tissue-resident memory (TRM) markers proved especially insightful for advancing our solid tumor program." Dr. Elena R.

"After treatment, accurately measuring residual CAR density on T cells was critical. Creative Biolabs not only resolved our ongoing tonic signaling issue but also delivered receptor downmodulation data that outperformed our internal flow cytometry core in both resolution and interpretability." Marcus H.

"The vesicle interference assay from Creative Biolabs served as key functional validation for our OMV-armored CAR-T platform. These results strengthened a major manuscript and were instrumental in closing our Series B financing round." Sarah V.

How to contact us?

Need to resolve tonic signaling or track receptor downmodulation after vesicle exposure? Our TIL and CAR-T phenotyping platform delivers publication‑ready data.

Let's accelerate your cell therapy analytics together.

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.